Lung cancer vaccine - AVAX Technologies

Drug Profile

Lung cancer vaccine - AVAX Technologies

Alternative Names: LungVax

Latest Information Update: 14 Dec 2015

Price : $50

At a glance

  • Originator AVAX Technologies
  • Class Cancer vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Non-small cell lung cancer

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 15 Sep 2015 No reports on development identified - Phase-I/II for Non-small cell lung cancer in USA (Parenteral)
  • 11 Apr 2008 The vaccine is still in phase I/II trials for Non-small lung cancer in the US
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top